Center for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA.
Center for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA; The George Washington School of Medicine and Health Sciences, Washington, DC, USA.
Cytotherapy. 2019 Sep;21(9):935-942. doi: 10.1016/j.jcyt.2019.04.058. Epub 2019 Jul 16.
T-cell lymphomas represent a subpopulation of non-Hodgkin lymphomas with poor outcomes when treated with conventional chemotherapy. A variety of novel agents have been introduced as new treatment strategies either as first-line treatment or in conjunction with chemotherapy. Immunotherapy has been demonstrated to be a promising area for new therapeutics, including monoclonal antibodies and adoptive cellular therapeutics. T-cell therapeutics have been shown to have significant success in the treatment of B-cell malignancies and are rapidly expanding as potential treatment options for other cancers including T-cell lymphomas. Although treating T-cell lymphomas with T-cell therapeutics has unique challenges, multiple targets are currently being studied both preclinically and in clinical trials.
T 细胞淋巴瘤是一种非霍奇金淋巴瘤亚群，用常规化疗治疗时预后较差。已经引入了多种新型药物作为一线治疗或与化疗联合的新治疗策略。免疫疗法已被证明是新疗法的一个有前途的领域，包括单克隆抗体和过继细胞治疗。T 细胞治疗在治疗 B 细胞恶性肿瘤方面已取得显著成功，并迅速扩展为包括 T 细胞淋巴瘤在内的其他癌症的潜在治疗选择。虽然用 T 细胞治疗剂治疗 T 细胞淋巴瘤具有独特的挑战，但目前正在临床前和临床试验中研究多个靶点。
